H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says Citizen Petitions usually do not result in withdrawals of products from the U.S. market, as over 80% of those filed since 2001 have been denied or failed to elicit a response from the FDA. It updated the company’s model post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics’ Earnings Call Highlights Success and Optimism
- Soleno Therapeutics price target raised to $120 from $115 at TD Cowen
- Soleno Therapeutics price target raised to $110 from $105 at Oppenheimer
- Soleno Therapeutics Reports Strong Q2 2025 Performance
- Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand